Analysis Now Expected News Today : Breaking News, Live Updates & Top Stories | Vimarsana

- Drove 18% Quarterly Net Revenue Growth of COSELA® Over the Fourth Quarter of 2022; Grew Quarterly Vial Volume by 21% Over Prior Quarter - - Provided Updated Timing for Interim Overall Survival. | May 3, 2023

United statesJack baileyJohnw umsteadWedbush pacgrowSacituzumab govitecan hziyRaymond jamesInvestor relations corporate communicationsExchange commissionEuropean society for medical oncologyAmerican society of clinical oncologyTherapeutics incResearch triangle parkNeedham companyDrug administration onQuarterly net revenue growthFourth quarter